THE IMPACT OF GLP-1 MEDICATIONS GOES FURTHER AND WIDER THAN ANYONE COULD HAVE EXPECTED. AND IT HAS HUGE IMPLICATIONS FOR BRANDS IN ALL SECTORS.
Havas is uniquely positioned at the intersection of consumer and healthcare sectors, allowing us to drive meaningful impact for our clients in this evolving landscape. We leverage our dual expertise in consumer and healthcare to help clients proactively consider, prepare for, and harness insights from the GLP-1 revolution in a rapidly changing market.
DOWNLOAD THE
PROSUMER REPORT
GLP-1s are a class of drug that were initially introduced over 8 years ago as a treatment for those with Type 2 diabetes (these are brands such as Ozempic, Trulicity, and Victoza). While the use of GLP-1s in diabetes has been important to the ongoing management of the condition, it is their weight loss indication and benefits that is creating seismic shifts in the world of biopharmaceuticals, culture, and nearly every market vertical.
GLP-1s will create a whole new relationship with companies creating health products, foods, travel, fashion, and more. Companies in these categories must act fast to anticipate the adjacent demands that come with rapid weight loss and management.
GLP1 DISRUPTION
IN THE PRESS
HAVAS HEALTH Press Release
Havas has launched a dedicated GLP-1 innovation consultancy to deliver tailored resources for brands to adapt to the dynamic landscape and adjacent markets accelerated by disruptor semaglutide drugs.
Op-Ed
Brian Robinson, Global Chief Strategy Officer and Head of Growth for Havas Health Network, and Mark Sinnock, Global Chief Strategy, Data, and Innovation Officer for Havas Creative Network wrote to Campaign US on the quiet disruption that semaglutides are having on just about every industry today. What does it mean for brands? It’s time for a GLP-1 plan.
WW Press Release
WeightWatchers unveiled “Beyond Hunger: Understanding Food Noise” report which offers insights into food noise and brings the topic to the forefront of the cultural conversation around weight bias, GLP-1 medications, and Weight Health.
Havas to Help Brands With Ozempic and Weight Loss Marketing Strategies
AdAge covered how Havas Health Network is trying to help marketers navigate the potential branding upheaval with a new consultancy meant to advise brands on strategies for the GLP-1 shift.
STRATEGIC IMPERATIVE: NAVIGATING CONSUMER BEHAVIORS IN THE AGE OF OZEMPIC
As breakthrough semaglutides (GLP1s) usher in a new wave of behaviors in healthcare, fashion, travel, fitness, CPGs and more – the single issue keeping marketers up at night is: How do we reach the less hungry, less impulsive, increasingly image-conscious consumer?
Join Havas as we discuss the transformative impact of GLP 1s, their far-reaching implications, evolving consumer profiles, and the critical role AI, data, and creativity play in understanding and responding to “The Ozempic Revolution.”
Date/Time: Monday, June 17th at 1:00 p.m.
• Donna Murphy, Global CEO of Havas Health and Havas Creative
• Brian Robinson, Chief Strategy Officer & Head of Growth at Havas Health
• Oodaye Shukla, Chief AI, Analytics, and Data Officer at Havas
• Chloé Depiesse, EVP, Head of Digital Strategy, Havas NOW